Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
1978 2
1979 5
1981 2
1982 5
1983 2
1984 1
1985 1
1986 6
1987 5
1988 6
1989 6
1990 11
1991 15
1992 9
1993 22
1994 21
1995 25
1996 24
1997 17
1998 24
1999 18
2000 20
2001 25
2002 19
2003 10
2004 10
2005 18
2006 11
2007 20
2008 16
2009 15
2010 11
2011 6
2012 15
2013 8
2014 11
2015 9
2016 9
2017 9
2018 7
2019 7
2020 5
2021 7
2022 13
2023 7
2024 8
2025 7
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Judson I, et al. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compar …
Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assess …
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
Gaspar N, Hung GY, Strauss SJ, Campbell-Hewson Q, Dela Cruz FS, Glade Bender JL, Koh KN, Whittle SB, Chan GC, Gerber NU, Palmu S, Morgenstern DA, Longhi A, Baecklund F, Lee JA, Locatelli F, Márquez Vega C, Janeway KA, McCowage G, McCabe MG, Bidadi B, Huang J, McKenzie J, Okpara CE, Bautista F; OLIE Study Investigators. Gaspar N, et al. JAMA Oncol. 2024 Dec 1;10(12):1645-1653. doi: 10.1001/jamaoncol.2024.4381. JAMA Oncol. 2024. PMID: 39418029 Free PMC article. Clinical Trial.
IMPORTANCE: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines. ...INTERVENTIONS: The OLIE trial assessed the efficacy and safety of lenvatini …
IMPORTANCE: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, …
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Powell MA, et al. J Clin Oncol. 2022 Mar 20;40(9):968-977. doi: 10.1200/JCO.21.02050. Epub 2022 Jan 10. J Clin Oncol. 2022. PMID: 35007153 Free PMC article. Clinical Trial.
PURPOSE: This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS: Adults with chemotherapy-naive UCS or ovari …
PURPOSE: This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclit …
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Grier HE, et al. N Engl J Med. 2003 Feb 20;348(8):694-701. doi: 10.1056/NEJMoa020890. N Engl J Med. 2003. PMID: 12594313 Free article. Clinical Trial.
BACKGROUND: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults. A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primi …
BACKGROUND: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescent …
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Fossella FV, et al. J Clin Oncol. 2000 Jun;18(12):2354-62. doi: 10.1200/JCO.2000.18.12.2354. J Clin Oncol. 2000. PMID: 10856094 Clinical Trial.
PATIENTS AND METHODS: A total of 373 patients were randomized to receive either docetaxel 100 mg/m(2) (D100) or 75 mg/m(2) (D75) versus a control regimen of vinorelbine or ifosfamide (V/I). The three treatment groups were well-balanced for key patient characteristics. ...
PATIENTS AND METHODS: A total of 373 patients were randomized to receive either docetaxel 100 mg/m(2) (D100) or 75 mg/m(2) (D75) versus a co …
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Nichols CR, et al. J Clin Oncol. 1998 Apr;16(4):1287-93. doi: 10.1200/JCO.1998.16.4.1287. J Clin Oncol. 1998. PMID: 9552027 Clinical Trial.
PURPOSE: To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide, and cisplatin (VIP) as primary treatment of men with advanced, disseminated germ cell tumors. ...CONCLUSION: BEP and VIP produce comparab …
PURPOSE: To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide …
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial.
Hiraga H, Machida R, Kawai A, Kunisada T, Yonemoto T, Endo M, Nishida Y, Nagano A, Ae K, Yoshida S, Asanuma K, Toguchida J, Furuta T, Nakayama R, Akisue T, Hiruma T, Morii T, Nishimura H, Hiraoka K, Takeyama M, Emori M, Tsukushi S, Hatano H, Kawashima H, Isu K, Tanaka K, Kataoka T, Fukuda H, Iwamoto Y, Ozaki T. Hiraga H, et al. J Clin Oncol. 2025 Jun;43(16):1886-1897. doi: 10.1200/JCO-24-01281. Epub 2025 Mar 26. J Clin Oncol. 2025. PMID: 40138604 Free PMC article. Clinical Trial.
PURPOSE: Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m(2) [4g/m(2) once on day 1, then 2g/m(2) once on days 2-7] six) to patients showing a poor response (PrRsp) to preoperative chemotherapy with methotr …
PURPOSE: Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m(2) [4g/m(2 …
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
Fan XL, Cai GP, Zhu LL, Ding GM. Fan XL, et al. Drug Des Devel Ther. 2015 Nov 4;9:5925-32. doi: 10.2147/DDDT.S91217. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26604690 Free PMC article. Review.
BACKGROUND: The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent. ...Eligible studies were clinical trials of patients with osteosarcoma who received ifosfamide-based chemotherapy. Ha …
BACKGROUND: The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results ar …
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Gisselbrecht C, et al. J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660832 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R …
PATIENTS AND METHODS: Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to …
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M; Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Verma S, et al. Cancer Treat Rev. 2008 Jun;34(4):339-47. doi: 10.1016/j.ctrv.2008.01.005. Epub 2008 Mar 3. Cancer Treat Rev. 2008. PMID: 18313854
RESULTS: Three randomized phase III trials were identified comparing combination chemotherapy regimens containing ifosfamide with regimens without ifosfamide. Two randomized trials demonstrated that the addition of ifosfamide to either doxorubicin or to a reg …
RESULTS: Three randomized phase III trials were identified comparing combination chemotherapy regimens containing ifosfamide with reg …
508 results